SCHEMBL15096166

SCHEMBL15096166

O=Cc1ccc(Oc2cccc(CO)c2)cc1

nearest known ligand 0.49

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
LTA4H P09960 1/20 0.49
PARP10 Q53GL7 1/20 0.46
PARP3 Q9Y6F1 1/20 0.46
FFAR1 O14842 5/20 0.44
SMN1; SMN2 Q16637 3/20 0.44
KDM4E B2RXH2 2/20 0.44
ALDH1A1 P00352 2/20 0.44
LMNA P02545 2/20 0.44
MAOA P21397 1/20 0.43
MAOB P27338 1/20 0.43
TSHR P16473 2/20 0.42
HTT P42858 1/20 0.42
FFAR4 Q5NUL3 1/20 0.42
TTR P02766 1/20 0.41
RAB9A P51151 1/20 0.41
PPARG P37231 1/20 0.40
PPARA Q07869 1/20 0.40
HSD17B10 Q99714 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21110860 0.88 MAOA (0.59) LTA4HFFAR1KDM4EALDH1A1MAOA
SCHEMBL24677897 0.83 FFAR1 (0.54) PARP10PARP3FFAR1FFAR4
SCHEMBL27230316 0.83 LTA4H (0.59) LTA4HPARP10PARP3SMN1; SMN2KDM4E
SCHEMBL8546955 0.82 ALDH1A1 (0.55) PARP10PARP3SMN1; SMN2KDM4EALDH1A1
SCHEMBL29661187 0.81 LTA4H (0.67) LTA4HFFAR1SMN1; SMN2KDM4EALDH1A1
SCHEMBL358425 0.81 LTA4H (0.67) LTA4HFFAR1SMN1; SMN2KDM4EALDH1A1
SCHEMBL12577967 0.80 RAB9A (0.62) FFAR1SMN1; SMN2KDM4EALDH1A1MAOA
SCHEMBL30979265 0.80 LTA4H (0.55) LTA4HFFAR1SMN1; SMN2LMNATSHR
SCHEMBL5112767 0.80 LTA4H (0.55) LTA4HFFAR1SMN1; SMN2LMNATSHR
SCHEMBL6853633 0.79 SRC (0.53) PARP10PARP3SMN1; SMN2KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9585850-B2 Methods of treatment using arylcyclopropylamine compounds DUKE UNIVERSITY (US) 2017-03-07 US disclosed
US-20150258044-A1 METHODS OF TREATMENT USING ARYLCYCLOPROPYLAMINE COMPOUNDS DUKE UNIVERSITY 2015-09-17 US disclosed
US-20140343118-A1 METHODS OF TREATMENT USING ARYLCYCLOPROPYLAMINE COMPOUNDS DUKE UNIVERSITY 2014-11-20 US disclosed
US-20130178520-A1 METHODS OF TREATMENT USING ARYLCYCLOPROPYLAMINE COMPOUNDS DUKE UNIVERSITY (US) 2013-07-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140343118-A1 METHODS OF TREATMENT USING ARYLCYCLOPROPYLAMINE COMPOUNDS BRCA1, NAT1, AADAC LTA4H 2801/4885PARP10 722/4885PARP3 203/4885
US-20150258044-A1 METHODS OF TREATMENT USING ARYLCYCLOPROPYLAMINE COMPOUNDS SNCA, PARK7, PNMT LTA4H 2299/4885PARP10 1384/4885PARP3 1302/4885
US-20130178520-A1 METHODS OF TREATMENT USING ARYLCYCLOPROPYLAMINE COMPOUNDS SNCA, PARK7, PNMT LTA4H 2299/4885PARP10 1384/4885PARP3 1302/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.